[1] Barnett P.Somatostatin and somatostatin receptor physiology.Endocrine,2003,20(3):255-264.
[2] Virgolini I,Traub T,Novotny C,et al.Experience with indium-111 and yttrium-90-labeled somatostatin analogs.Curr Pharm Des.2002,8(20):1781-1807.
[3] 汪静,邓敬兰,武胜昔,等.生长抑素受体家族mRNA在肺癌中分布与表达的研究.中华核医学杂志,2000,20(1):16-18.
[4] Bohuslavizki KH.Somatostatin receptor imaging:current status and future perspectives.J Nucl Med,2001,42(7):1057-1058.
[5] 王峰,王自正,姚薇萱,等.99mTc-生长抑素受体显像对肺癌的诊断价值.中华结核和呼吸杂志,2005,28(4):218-220.
[6] Oberg K,Eriksson B.Nuclear medicine in the detection,staging and treatment of gastrointestinal carcinoid tumours.Best Pract Res Clin Endocrinol Metab,2005,19(2):265-276.
[7] Saga T,Shimatsu A,Koizumi K,et al.Morphological imaging in the localization of neuroendocrine gastroenteropancreatic tumors found by somatostatin receptor scintigraphy.Acta Radiol,2005,46(3):227-232.
[8] Forssell-Aronsson EB,Nilsson Q,Benjegard S,et al.111In-DTPA-D-Phel-octreotide binding and somatostatin receptor subtype in thyroid tumor.J Nucl Med,2000,41(4):636-642.
[9] Kahn D,Menda Y,Kernstine K,et al.The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.Chest,2004,125(2):494-501.
[10] Shih WJ,Samayoa L.Tc-99m Depreotide detecting malignant pulmonary nodules:histopathologic correlaton with semiquantitative tumor-to-normal lung ratio.Clin Nucl Med,2004,29(3):171-176.
[11] Hellwig D,Samnick S,Reif J,et al.Comparison of Tc-99m depreotide and In-111 octreotide in recurrent meningioma.Clini Nucl Med,2002,27(11):781-784.